Shire Articles
Shire's Fosrenol fares well in Ph II CKD study
12 November 2007
Dynepo demonstrates reduced angiogenesis in preclinical trial
12 November 2007
FDA's CRDAC votes to expand P binders in CKD
29 October 2007
Stock Commentary - Europe - week to October 15, 2007
22 October 2007
US FDA to consider phosphate binders for kidney disease
22 October 2007
Japan's MHLW OKs Shire's Elaprase
15 October 2007
Canada issues WTO compulsory license for HIV/AIDS drug
8 October 2007
Syvlie Gregoire named president of Shire's Human Genetic Therapies unit
27 September 2007
Validus acquires Shire's Equetro
17 September 2007
Promotions at Shire in Spain and UK
17 September 2007
NICE complies with UK court's AD ruling
17 September 2007
Shire orders limited recall of Daytrana patch
10 September 2007
NICE announce AD drug clarification "within 28 days"
20 August 2007
Shire to discontinue heart drug Ethmozine
13 August 2007
Cosmo's 1st-half loss up 325% on R&D costs
13 August 2007
Shire's Vyvanse made available in USA
6 August 2007
Stock Commentary - Europe - week to July 30, 2007
6 August 2007
Shire makes $30M investment in USA
30 July 2007
Banned drugs "sold freely" in India
23 July 2007
Stock Commentary - Europe - week to July 9, 2007
16 July 2007
Alzheimer's case concludes in UK High Court
9 July 2007
Shire submits sNDA for Vyvanse to US FDA
9 July 2007
UK court puts NICE AD drug limits on trial
2 July 2007
Shire's Intuniv gets "approvable" FDA letter
2 July 2007
Canada OKs Elaprase for Hunter syndrome
25 June 2007
Samaritan to sell Shire
4 June 2007
Shire to review options after US SPD465 delay
28 May 2007
UK NICE AD drug policy hearing set for June 25
21 May 2007
UK's NICE blamed for poor cancer care
21 May 2007
Stock Commentary - Europe - week to May 7, 2007
14 May 2007
Vyvanse classified as Schedule II by US DEA
14 May 2007
Shire refinances with $1B bond
7 May 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
"Record number" of drugs in UK pipeline
30 April 2007
Shire completes tender offer for New River
23 April 2007
Shire's David Pendergast to retire at year end
26 March 2007
ABPI "admonishes" Servier and Shire
26 March 2007
Shire's proposed purchase of New River progresses
26 March 2007
Shire debuts Lialda in USA
26 March 2007
New River's FY 2006 loss deepens to $57M
26 March 2007
Shire close to European launch of Dynepo
19 March 2007
Stock Commentary - Europe - week to Feb 26, 2007
5 March 2007
Shire launches Fosrenol in UK
5 March 2007
Shire secures successor to Adderall XR as US FDA approves Vyvanse: another predicted blockbuster
5 March 2007
Dainippon Sumitomo launches Replagel in Japan
26 February 2007
Shire's 2006 income hits $278M, sales up 16%
26 February 2007
Japan stock market week to Feb 19, 2007
26 February 2007
Shire to purchase New River for $2.6B in cash
26 February 2007
Cosmo seeks listing on SWX exchange
19 February 2007
Shire extends deal with Avexa
29 January 2007
Shire's Lialda cleared by US FDA
22 January 2007
Shire's Elaprase gets EU OK for Hunter synd
22 January 2007
Shire's Elaprase gets EU OK for Hunter synd
22 January 2007
Stock Commentary - Europe - week to Jan 1, 2007
8 January 2007
Vyvanse receives 2nd FDA approvable letter
8 January 2007
Bayer Yakuhin files Fosrenol in Japan
22 December 2006
Cosmo's out-licensed MMX technology gets EU labeling OK
22 December 2006
Shire targets Q1 07 EU launch of Mezavant
22 December 2006
Australia OKs Shire's Solaraze for AK
11 December 2006
Shire's ADHD drug impresses in Phase III trial
27 November 2006
Stock Commentary - Europe - week to Nov 20, 2006
27 November 2006
Shire "disappointed" at NICE's AD decision
27 November 2006
Fosrenol as effective as standard therapy in hyperphosphatemia
27 November 2006
Stimulant-based ADHD drugs superior to alternatives, says study
27 November 2006
SPD465 equivalent to Adderall XR plus MAS-IR in adult ADHD
27 November 2006
Is AstraZeneca eyeing up Shire for a buy?
27 November 2006
Shire's MMX mesalazine performs well in UC studies
13 November 2006
Strong data on Shire's long-acting ADHD drug
13 November 2006
Stock Commentary - Europe - week to Oct 30, 2006
6 November 2006
Shire's 3rd-qtr 2006 revenue rises 19%
6 November 2006
Shire launches Ph IIIb Dynepo trial
6 November 2006
Replagel cleared for pediatric Fabry disease
30 October 2006
Shire's Elaprase gets nod from EMEA's CHMP
30 October 2006
Stock Commentary - Europe - week to Oct 16, 2006
23 October 2006
New River updates on NRP290
23 October 2006
Stock Commentary - Europe - week to Oct 9, 2006
16 October 2006
NICE rules out dementia drugs for mild AD
16 October 2006
Andrx files ANDA for generic version of Shire's Adderall XR
9 October 2006
Shire licenses TPC from Warren Pharma
9 October 2006
Stock Commentary - Europe - week to Sept 25, 2006
2 October 2006
AnorMed set to receive $3M from Shire
2 October 2006
Good anemia control in CKD for Shire's Dynepo
25 September 2006
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
